Clinical trials: Patients With Major Depressive Disorder
Depression, Depressive Disorder
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major
- Trial name
- UPLIFT (NCT05686408)
- Testing
- TNX-601 ER
- Where
- 27 sites in United States
- Volunteers
- 132 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Major Depressive Disorder
Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment
Background. Depression is a highly frequent condition in the elderly, with a huge impact on quality of life, life expectancy, and medical outcomes.
- Trial name
- VESPA (NCT03779789)
- Testing
- Vortioxetine, Sertraline, citalopram
- Where
- 3 sites in Italy
- Volunteers
- 362 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Major Depressive Disorder
Efficacy of Electronic Cognitive Behavioral Therapy Application to Treat Major Depressive Disorder
The primary objective of this study is to evaluate the safety and efficacy of an electronic cognitive behavioral therapy application (eCBT Mood) compared to a control group consisting of a mood monitoring handheld computer…
- Trial name
- NCT01752608
- Testing
- eCBT Mood
- Where
- 2 sites in United States
- Sponsor
- MindApps
Major Depressive Disorder
A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression
This study is a retrospective database study in Japan to evaluate the relative risk of serious intracranial hemorrhage requiring hospitalization between Vortioxetine tablet treatment and selective serotonin reuptake inhibitor…
- Trial name
- NCT05932407
- Testing
- Vortioxetine Tablet, SSRI
- Where
- Japan
- Volunteers
- 147,777 people
- Sponsor
- Takeda
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression
- Trial name
- NCT00035009
- Testing
- MK0869, aprepitant, Comparator: paroxetine HCL
- Volunteers
- 468 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depression
Cognitive Behavioral Treatments for Depression in Chronic Illness
Duke University Medical Center in collaboration with Glendale Adventist Medical Center propose a randomized clinical trial of conventional cognitive behavior therapy (CCBT) vs.
- Trial name
- NCT01208428
- Testing
- Conventional cognitive behavioral therapy, Religious cognitive behavioral therapy
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Duke University
Major Depressive Disorder
Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients
Our hypothesis is that using antidepressants during the ECT has a better efficacy and longer time to relapse/recurrence to the ECT without antidepressants.
- Trial name
- NCT04181567
- Testing
- electroconvulsive therapy, agomelatine
- Where
- Taiwan
- Volunteers
- 97 people
- Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
Pulmonary Disease, Chronic Obstructive, Major Depression
Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients
Approximately 20% of patients with chronic obstructive pulmonary disease (COPD) have major depression, a condition that contributes to suffering but also to poor treatment adherence leading to increased disability and morbidity.
- Trial name
- NCT00151372
- Testing
- Treatment Adherence Intervention, Enhanced Care
- Where
- 3 sites in United States
- Volunteers
- 141 people
- Sponsor
- Weill Medical College of Cornell University
Major Depression
Functional Neuroimaging in Depression
Oral administration of escitalopram during 8 weeks; PET scan with 18F-FDG at inclusion and after 8 weeks
- Trial name
- NCT00343070
- Testing
- Oral administration of escitalopram during 8 weeks
- Where
- 2 sites in Belgium
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ghent
Schizophrenia, Major Depressive Disorder
Effectiveness of Traditional Chinese Metacognitive Training (MCT) in Patients With Schizophrenia, Depression, or Bipolar Disorder Attending a Psychiatric Day Hospital in Taiwan
Schizophrenia is characterized by positive symptoms such as delusions and hallucinations, which significantly impact daily functioning.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT07051746
- Testing
- Metacognitive Training (MCT), Traditional Chinese version
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- ZI-YU LIN
Major Depressive Disorder
Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder
The current study is being conducted in patients with major depression. The study aims to 1) investigate the combined effects of selective serotonin reuptake inhibitor (SSRI) and bupropion compared to SSRI alone on the…
- Trial name
- NCT01541475
- Testing
- Bupropion, Escitalopram, Escitalopram
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Ewha Womans University
Major Depressive Disorder
Trazodone Once a Day in Major Depression Disorder
The study objective is to evaluate the efficacy and safety of trazodone OAD vs venlafaxine extended release (venlafaxine XR) after an 8-week treatment period in patients with major depressive disorder.
- Trial name
- NCT02086929
- Testing
- Trazodone, Venlafaxine
- Where
- 32 sites in Austria, Czechia and 4 more
- Volunteers
- 364 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Patients Diagnosed With Severe Mental Illness
From Compliance to Alliance: Engaging Psychiatric Patients in Illness Management
The purpose of this study is to determine the benefit and impact on relapse prevention,adherence to treatment and general health indices of participation in psycho-eduational group intervention among psychiatric patients with…
- Trial name
- NCT00192751
- Testing
- Psychoeducational group sessions
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- Rambam Health Care Campus
Depressive Disorder, Major
The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder
This is a phase 2 and 3 adaptive design study for Mitizodone Phosphate,to find out an optimal dose in phase 2 period and confirm the result an efficacy and safety in phase 3 period.Dose-finding will be done after 8 weeks of…
- Trial name
- NCT04984512
- Testing
- Mitizodone Phosphate tablets
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Depression
Vortioxetine to Prevent Return of Symptoms in Children With Depression
The purpose of this study is to find out if vortioxetine is better than placebo (sugar pills) in preventing depression in children who improved when treated with vortioxetine.
- Trial name
- NCT05014919
- Testing
- Vortioxetine
- Where
- 17 sites in United States, Colombia and 5 more
- Volunteers
- 35 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD
- Trial name
- NCT01715805
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 85 sites in United States, Puerto Rico
- Volunteers
- 1,022 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder
To evaluate if somatosensory evoked potentials (SEPs) and motor evoked potentials (MEPs) obtained with electroencephalography (EEG) and electromyography (EMG) can be used to detect changes in cortical plasticity in responders to…
- Trial name
- NCT01957410
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder
The goal of this observational study is to learn about how Pristiq is currently being used in general practice and how psychiatrists and primary care physicians currently perceive Pristiq in terms of efficacy, tolerability, and…
- Trial name
- NCT01221935
- Testing
- Pristiq first-line treatment charts, Pristiq second-line treatment charts, SNRI or SSRI first-line treatment charts
- Volunteers
- 2,701 people
- Sponsor
- Pfizer
Depression
Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder
Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the severity of anxiety and depression, sleep state…
- Trial name
- FRIENDS (NCT02043197)
- Where
- 29 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Abbott
Major Depressive Disorder, Metabolic Syndrome
Incidence of Metabolic Syndrome and Thyroid Dysfunction in Patients With Major Depressive Disorder
Aim 1 is to study prevalence and 1 year incidence of metabolic syndrome in major depressive disorder and factors correlation. Aim 2 is to study prevalence and 1 year incidence of thyroid dysfunction in major depressive disorder…
- Conditions
- Major Depressive Disorder, Metabolic Syndrome, Thyroid Dysfunction
- Trial name
- NCT01682785
- Volunteers
- 140 people
- Sponsor
- Chiang Mai University